Skip to Content
Morningstar

Biomarin Pharmaceutical Inc BMRN

Morningstar Rating
Unlock
Stock XNAS Rating as of
$92.06 +2.57 (2.87%)
View Full Chart
As of Delayed Price Closed
Unlock our analysis with Morningstar Investor
Start Free Trial

Company Report

View Archive

BioMarin's Diversified Rare Disease Business Supports a Narrow Moat

Karen Andersen

BioMarin is amassing a portfolio of genetic-disease therapeutics, making historical comparisons with Genzyme (acquired by Sanofi) difficult to avoid. Commercialization and research and development expenses kept BioMarin in the red for years despite multiple approved products, but we're confident in the sustainable, profit-generating power of its current portfolio. With a deep in-house pipeline and the ability to supplement growth with strategic acquisitions, BioMarin is in a strong position.

Read Full Report

Price vs Fair Value

View History
BMRN is trading at a 7% discount.
Price
$89.49
Fair Value
$29.00
Uncertainty
High
1-Star Price
$153.50
5-Star Price
$12.10
Economic Moat
Qwpqcxt
Capital Allocation
Jyvztkrlq

Bulls Say, Bears Say

Bulls

BioMarin's approved drugs have been granted orphan-drug status in the US and EU, providing them with at least 7 and 10 years of market exclusivity, respectively.

Bears

Diagnosis of rare genetic diseases can be difficult, and BioMarin could have a hard time locating enough patients to recoup development and manufacturing costs.

Show More
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if BMRN is a good fit for your portfolio.
Get 7 Days Free

News

View All

Trading Information

Previous Close Price
$89.49
Day Range
$89.93–92.22
52-Week Range
$76.02–99.56
Bid/Ask
$90.89 / $93.33
Market Cap
$17.47 Bil
Volume/Avg
1.3 Mil / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
110.92
Price/Sales
7.29
Dividend Yield (Trailing)
—
Dividend Yield (Forward)
—
Total Yield
—

Company Profile

BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Mid Growth
Total Number of Employees
3,401
Website
https://www.biomarin.com

Competitors

Valuation

View More
Metric
BMRN
SNY
PFE
Price/Earnings (Normalized)
 110.9210.0414.27
Price/Book Value
 3.501.561.67
Price/Sales
 7.292.382.53
Price/Cash Flow
 35.5711.6613.63
Price/Earnings
BMRN
SNY
PFE

Financial Strength

Metric
BMRN
SNY
PFE
Quick Ratio
 1.450.830.58
Current Ratio
 2.511.270.91
Interest Coverage
 8.7811.030.74
Quick Ratio
BMRN
SNY
PFE

Profitability

Metric
BMRN
SNY
PFE
Return on Assets (Normalized)
 6.15%8.05%4.98%
Return on Equity (Normalized)
 8.47%14.38%10.90%
Return on Invested Capital (Normalized)
 6.27%10.85%7.28%
Return on Assets
BMRN
SNY
PFE
See how this stock stacks up to its competitors with Morningstar Investor
Start Free Trial

Biotechnology Industry Comparables

Screen in Investor
Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRCkmjcjfqvkKlhr$557.8 Bil
VRTX
Vertex Pharmaceuticals IncJhtdkqgRpclkld$104.7 Bil
REGN
Regeneron Pharmaceuticals IncVdpxgtvpBcqydpx$98.8 Bil
MRNA
Moderna IncNtgtdhqdJlwh$38.8 Bil
ARGX
argenx SE ADRXdhjjxjwhNnblz$21.4 Bil
BNTX
BioNTech SE ADRMmhzypvnRjqtn$20.8 Bil
ALNY
Alnylam Pharmaceuticals IncCjvknhdxSjskt$18.4 Bil
RPRX
Royalty Pharma PLC Class ACxvjmxrwqQfwglpf$12.4 Bil
INCY
Incyte CorpHhdmtgmGmkztr$11.9 Bil

Sponsor Center